No. 8: Danaher (life sciences, diagnostics & dental segments)
2017 revenues: $14,360,900,000
2017 R&D spend: $939,100,000
Fiscal year ending: December 31, 2017
Thomas Joyce Jr., president & CEO; Daniel Comas, EVP & CFO; Rainer Blair, EVP, life sciences; William Daniel II, EVP, diagnostics & dental; Brian Ellis, SVP & general counsel; William King IV, SVP, strategic development; Angela Lalor, SVP, HR; Robert Lutz, SVP & chief accounting officer; Daniel Raskas, SVP, corporate development
Danaher refined its shift toward the life sciences with the July 2018 news that it’s planning to spin out its $3 billion dental business. The new entity, DentalCo, is slated to go through during the second half of 2019. It’s expected to be led by Amir Aghdaei as president & CEO, who runs the dental unit as group executive; the dental segment employs about 12,000 workers from the Nobel Biocare, Ormco and KaVo Kerr businesses.